Characterization of novel histidine-tagged Tat-peptide complexes dual-labeled with 99mTc-tricarbonyl and fluorescein for scintigraphy and fluorescence microscopy

Bioconjugate Chemistry

Volumn 13, Issue 6, 2002, Pages 1226-1237

  Bullok, Kristin E ^a   Dyszlewski, Mary ^a   Prior, Julie L ^a   Pica, Christina M ^a   Sharma, Vijay ^a   Piwnica Worms, David ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; DATA VISUALIZATION; FLUORESCENCE; FLUORESCENCE MICROSCOPY; MOLECULAR IMAGING; PEPTIDES;

BIODISTRIBUTIONS; C-TERMINUS; IN-VIVO; LOCALISATION; MALEIMIDES; PEPTIDE COMPLEX; SUBCELLULAR LOCALIZATIONS; SYNTHESISED; TAT PEPTIDE; WHOLE-BODY;

CHELATION;

ANIMALIA;

EID: 0036860781     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc025573a     Document Type: Article

References (47)

1. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev. 99, 2235-2268.
2. Schwarze, S., Hruska, K., and Dowdy, S. (2000) Protein transduction: Unrestricted delivery into all cells? Trends Cell Biol. 10, 290-295.
3. Frankel, A., and Pabo, C. (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55, 1189-1193.
4. Green, M., and Loewenstein, P. (1988) Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55, 1179-1188.
5. Schluesener, H. (1996) Protection against experimental nervous system autoimmune diseases by a human immunodeficeincy virus-1 Tat peptide-based polyvalent vaccine. J. Neurosci. Res. 46, 258-262.
6. Vives, E., Brodin, P., and Lebleu, B. (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272, 16010-16017.
7. Josephson, L., Tung, C.-H., Moore, A., and Weissleder, R. (1999) High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjugate Chem. 10, 186-191.
8. Vocero-Akbani, A., Heyden, N., Lissy, N., Ratner, L., and Dowdy, S. (1999) Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat. Med. 5, 29-33.
9. Schwarze, S., Ho, A., Vocero-Akbani, A., and Dowdy, S. (1999) In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 285, 1569-1572.
10. Bhorade, R., Weissleder, R., Nakakoshi, T., Moore, A., and Tung, C. (2000) Macrocyclic chelators with paramagnetic cations are internalized in to mammalian cells via a HIV-Tat derived membrane translocation peptide. Bioconjugate Chem. 11, 301-305.
11. Fischer, P. M., Krausz, E., and Lane, D. P. (2001) Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation. Bioconjugate Chem. 12, 825-841.
12. Wunderbaldinger, P., Josephson, L., and Weissleder, R. (2002) Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. Bioconjugate Chem. 13, 264-268.
13. Polyakov, V., Sharma, V., Dahlheimer, J., Pica, C., Luker, G., and Piwnica-Worms, D. (2000) Novel Tat-peptide chelates for direct transduction of technetium-99m and rhenium into human cells for imaging and radiotherapy. Bioconjugate Chem. 11, 762-771.
14. Schwochau, K. (1994) Technetium radiopharmaceuticals - Fundamentais, synthesis, structure and development. Angew. Chem., Int. Ed. Engl. 33, 2258-2267.
15. Hom, R., and Katzenellenbogen, J. (1997) Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals: Recent developments and encouraging results. Nucl. Med. Biol. 24, 485-498.
16. Jurisson, S., and Lydon, J. (1999) Potential technetium small molecule radipharmaceuticals. Chem. Rev. 99, 2205-2218.
17. Volkert, W., and Hoffman, T. (1999) Therapeutic radiopharmaceuticals. Chem. Rev. 99, 2269-2292.
18. 3L] (L = Bis(bis(hydroxymethyl)-phosphino)ethane, Bis(bis(hydroxymethyl)phosphino)benzene). Inorg. Chem. 40, 2358-2362.
19. Waibel, R., Alberto, R., Willuda, J., Finnern, R., Schibli, R., Stichelberger, A., Egli, A., Abram, U., Mach, J.-P., Pluckthun, A. et al. (1999) Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat. Biotech. 17, 897-901.
20. - in aqueous solution and its reaction with a bifunctional ligand. J. Am. Chem. Soc. 120, 7987-7988.
21. 3 moieties to biologically active molecules. Bioconjugate Chem. 11, 414-424.
22. +. J Am Chem Soc. 123, 3135-3136.
23. Achilefu, S., Wilhelm, R. R., Jimenez, H. N., Schmidt, M. A., and Srinivasan, A. (2000) A new method for the synthesis of tri-tert-butyl diethylenetriaminepentaacetic acid and its derivatives. J. Org. Chem. 65, 1562-1565.
24. Feng, Y., Wang, Z., Jin, S., and Burgess, K. (1998) SNAr cyclization to form cyclic peptidomimetics of beta-turns. J. Am. Chem. Soc. 120, 10768-10769.
25. 6]. Polyhedron 15, 1079-1080.
26. 111In-labeled DTPA-peptide cojugates. Bioconjugate Chem. 12, 630-634.
27. 99mTc-labeled radiopharmaceuticals. Semin. Nucl. Med. 20, 5-27.
28. Akiyama, S. I., Fojo, A., Hanover, J. A., Pastan, I., and Gottesman, M. M. (1985) Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somatic Cell Mol. Genet. 11, 117-126.
29. Piwnica-Worms, D., Chiu, M., Budding, M., Kronauge, J., Kramer, R., and Croop, J. (1993) Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 53, 977-984.
30. -: Carrier free? J. Nucl. Med. 16, 639-641.
31. Piwnica-Worms, D., Kronauge, J., and Chiu, M. (1990) Uptake and retention of hexakis (2-methoxy isobutyl isonitrile) technetium(I) in cultured chick myocardial cells: Mitochondrial and plasma membrane potential dependence. Circulation 82, 1826-1838.
32. Rao, V., Dahlheimer, J., Bardgett, M., Snyder, A., Finch, R., Sartorelli, A., and Piwnica-Worms, D. (1999) Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal fluid drug-permeability barrier. Proc. Natl. Acad. Sci. U.S.A. 96, 3900-3905.
33. Luker, G., Sharma, V., Pica, C., Dahlheimer, J., Li, W., Ochesky, J., Ryan, C., Piwnica-Worms, H., and Piwnica-Worms, D. (2002) Noninvasive imaging of protein-protein interactions in living animals. Proc. Natl. Acad. Sci. U.S.A. 99, 6961-6966.
34. 99mTc(I)-tricarbonyl complexes: A hint for the future functionalization of biomolecules. Bioconjugate Chem. 11, 345-351.
35. 99mTc. J Am Chem Soc. 121, 6076-6077.
36. Mann, D., and Frankel, A. (1991) Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J. 10, 1733-1739.
37. Fawell, S., Seery, J., Daikh, Y., Moore, C., Chen, L., Pepinsky, B., and Barsoum, J. (1994) Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. U.S.A. 91, 664-668.
38. Wender, P., Mitchell, D., Pattabiraman, K., Pelkey, E., Steinman, L., and Rothbard, J. (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters. Proc. Natl. Acad. Sci. U.S.A. 97, 13003-13008.
39. Lee, H. J., and Pardridge, W. M. (2001) Pharmacokinetics and delivery of Tat and Tat-protein conjugates to tissues in vivo. Bioconjugate Chem. 12, 995-999.
40. Eguchi, A., Akuta, T., Okuyama, H., Senda, T., Yokoi, H., Inokuchi, H., Fujita, S., Hayakawa, T., Takeda, K., Hasegawa, M. et al. (2001) Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells. J. Biol. Chem. 276, 26204-26210.
41. Ho, A., Schwarze, S. R., Mermelstein, S. J., Waksman, G., and Dowdy, S. (2001) Synthetic protein transduction domains: Enhanced transduction potential in vitro and in vivo. Cancer Res. 61, 474-477.
42. Decristoforo, C., and Mather, S. (1999) Technetium-99m somatostatin analogues: Effect of labeling methods and peptide sequence. Eur. J. Nucl. Med. 26, 869-876.
43. Liu, Y., Jones, M., Hingtgen, C., Bu, G., Laribee, N., Tanzi, R., Moir, R., Nath, A., and He, J. (2000) Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat. Med. 6, 1380-1387.
44. Qu, T., Wang, Y., Zhu, Z., Rusckowski, M., and Hnatowich, D. (2001) Different chelators and different peptides together influence the in vitro and mouse in vivo properties of 99Tcm. Nucl. Med. Commun. 22, 203-215.
45. Niesner, U., Halin, C., Lozzi, L., Günthert, M., Neri, P., Wunderli-Allenspach, H., Zardi, L., and Neri, D. (2002) Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 Tat peptides. Bioconjugate Chem. 13, 729-736.
46. Rousselle, C., Clair, P., Lefauconnier, J.-M., Kaczorek, M., Scherrmann, J.-M., and Temsamani, J. (2000) New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol. 57, 679-686.
47. Rousselle, C., Smirnova, M., Clair, P., Lefauconnier, J.-M., Chavanieu, A., Calas, B., Scherrmann, J.-M., and Temsamani, J. (2001) Enhanced delivery of doxorubicin into the brain via a peptide-vector- mediated strategy: Saturation kinetics and specificity. J. Pharmacol. Exp. Ther. 296, 124-131.